TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%

Reuters

11/14

<a href="https://laohu8.com/S/TELA">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%

TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583147511"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583147511\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583147511?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583147511","market":"fut","top_or_hot":-1,"title":"TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-14 05:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Inc. reports Q3 revenue of $20.7 million, up 9%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL6YNG09:1","article_id":"2583147511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583147511","pubTimestamp":1763067676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-onl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4198":"医疗保健用品","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","TELA":"TELA Bio, Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"TELA Bio Inc.报告第三季度收入为2070万美元，增长9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TELA":0.9},"content_text":"TELA Bio Inc. reports Q3 revenue of $20.7 million, up 9%\n    \n\n        TELA Bio Inc. reported third quarter 2025 revenue of $20.7 million, representing a 9% increase compared to the same period in 2024. Gross profit for the quarter was $14.0 million, or 67.5% of revenue, up from $12.9 million, or 67.8% of revenue, in the third quarter of 2024. The revenue growth was primarily driven by new customer additions, increased international sales, and the U.S. launch of larger-sized OviTex PRS configuration, partially offset by a decrease in average selling prices for hernia products due to a higher share of smaller-sized units. The company revised its full year 2025 revenue guidance to at least 16% growth over 2024. As of September 30, 2025, cash and cash equivalents totaled $29.7 million. TELA Bio also closed a credit facility for up to $70.0 million with Perceptive Advisors, consisting of an initial $60.0 million loan and an additional $10.0 million available upon meeting certain conditions. The credit facility matures on November 14, 2030, and is interest-only until maturity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575463-en) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}